These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27043285)

  • 21. Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma.
    Condelli V; Maddalena F; Sisinni L; Lettini G; Matassa DS; Piscazzi A; Palladino G; Amoroso MR; Esposito F; Landriscina M
    Oncotarget; 2015 Sep; 6(26):22298-309. PubMed ID: 26084290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRAP1 regulation of mitochondrial life or death decision in cancer cells and mitochondria-targeted TRAP1 inhibitors.
    Kang BH
    BMB Rep; 2012 Jan; 45(1):1-6. PubMed ID: 22281005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF signaling and targeted therapies in melanoma.
    Dhomen N; Marais R
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):529-45, ix. PubMed ID: 19464601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma.
    Smith LK; Rao AD; McArthur GA
    Pharmacol Res; 2016 May; 107():42-47. PubMed ID: 26924126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failed upregulation of TFAM protein and mitochondrial DNA in oxidatively deficient fibers of chronic obstructive pulmonary disease locomotor muscle.
    Konokhova Y; Spendiff S; Jagoe RT; Aare S; Kapchinsky S; MacMillan NJ; Rozakis P; Picard M; Aubertin-Leheudre M; Pion CH; Bourbeau J; Hepple RT; Taivassalo T
    Skelet Muscle; 2016; 6():10. PubMed ID: 26893822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Landscape of the mitochondrial Hsp90 metabolome in tumours.
    Chae YC; Angelin A; Lisanti S; Kossenkov AV; Speicher KD; Wang H; Powers JF; Tischler AS; Pacak K; Fliedner S; Michalek RD; Karoly ED; Wallace DC; Languino LR; Speicher DW; Altieri DC
    Nat Commun; 2013; 4():2139. PubMed ID: 23842546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.
    Schaefer S; Svenstrup TH; Guerra B
    PLoS One; 2017; 12(5):e0177706. PubMed ID: 28542269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells.
    Basit F; van Oppen LM; Schöckel L; Bossenbroek HM; van Emst-de Vries SE; Hermeling JC; Grefte S; Kopitz C; Heroult M; Hgm Willems P; Koopman WJ
    Cell Death Dis; 2017 Mar; 8(3):e2716. PubMed ID: 28358377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
    Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.
    Richard G; Dalle S; Monet MA; Ligier M; Boespflug A; Pommier RM; de la Fouchardière A; Perier-Muzet M; Depaepe L; Barnault R; Tondeur G; Ansieau S; Thomas E; Bertolotto C; Ballotti R; Mourah S; Battistella M; Lebbé C; Thomas L; Puisieux A; Caramel J
    EMBO Mol Med; 2016 Oct; 8(10):1143-1161. PubMed ID: 27596438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
    Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PGC-1α in Melanoma: A Key Factor for Antioxidant Response and Mitochondrial Function.
    Torrens-Mas M; González-Hedström D; Abrisqueta M; Roca P; Oliver J; Sastre-Serra J
    J Cell Biochem; 2017 Dec; 118(12):4404-4413. PubMed ID: 28452072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
    Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90.
    Kang BH; Plescia J; Song HY; Meli M; Colombo G; Beebe K; Scroggins B; Neckers L; Altieri DC
    J Clin Invest; 2009 Mar; 119(3):454-64. PubMed ID: 19229106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted inhibition of mitochondrial Hsp90 induces mitochondrial elongation in Hep3B hepatocellular carcinoma cells undergoing apoptosis by increasing the ROS level.
    Yoo SH; Kim HY; Rho JH; Jeong SY; Yun J; Yun I; Park HT; Yoo YH
    Int J Oncol; 2015 Nov; 47(5):1783-92. PubMed ID: 26351876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.